blog/videos

Food And Drug Administration Approves New Libido-Boosting Drug for Premenopausal Ladies

The usa Food and Drug management (Food And Drug Administration) today authorized bremelanotide (Vyleesi, AMAG Pharmaceuticals), a melanocortin that is first-in-class receptor agonist for hypoactive sexual interest disorder (HSDD) in premenopausal females.

It joins flibanserin (Addyi, Sprout Pharmaceuticals), truly the only other FDA-approved HSDD treatment plan for premenopausal females.

The Food And Drug Administration had until 23 to complete the review of bremelanotide’s new drug application (NDA) under the Prescription Drug User Fee Act (PDUFA) june. Continue reading